Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
A survey on cellular and engineered tissue therapies in Europe in 2008
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1193398
Author(s) Martin, Ivan; Baldomero, Helen; Tyndall, Alan; Niederwieser, Dietger; Gratwohl, Alois
Author(s) at UniBasel Gratwohl, Alois A.
De Vere-Tyndall, Alan
Martin, Ivan
Year 2010
Title A survey on cellular and engineered tissue therapies in Europe in 2008
Journal Tissue engineering. Part A
Volume 16
Number 8
Pages / Article-Number 2419-27
Abstract Cellular therapy is an evolving investigational treatment modality in regenerative medicine, but little published information is available on its current use. Starting from the established European group for Blood and Marrow Transplantation activity survey on hematopoietic stem cell transplantation, a joint committee of four major scientific organizations made a coordinated attempt to collect detailed information in Europe for the year 2008. Thirty-three teams from 16 countries reported data on 656 patients to a "novel cellular therapy" survey, which were combined to additional 384 records reported to the standard European group for Blood and Marrow Transplantation survey. Indications were cardiovascular (29%; 100% autologous), musculoskeletal (18%; 97% autologous), neurological (9%; 39% autologous), epithelial/parenchymal (9%; 18% autologous), autoimmune diseases (12%; 77% autologous), or graft-versus-host disease (23%; 13% autologous). Reported cell types were hematopoietic stem cells (39%), mesenchymal stromal cells (47%), chondrocytes (5%), keratinocytes (7%), myoblasts (2%), and others (1%). In 51% of the grafts, cells were delivered after expansion; in 4% of the cases, cells were transduced. Cells were delivered intravenously (31%), intraorgan (45%), on a membrane or gel (14%), or using three-dimensional scaffolds (10%). This data collection platform is expected to capture and foresee trends for novel cellular therapies in Europe, and warrants further consolidation and extension.
Publisher Mary Ann Liebert
ISSN/ISBN 1937-3341
edoc-URL http://edoc.unibas.ch/dok/A6003641
Full Text on edoc Available
Digital Object Identifier DOI 10.1089/ten.TEA.2010.0056
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/20184422
ISI-Number WOS:000280648700002
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.356 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
29/03/2024